C-MOT: Copenhagen Master Observational Trial

Sponsor

Rigshospitalet, Denmark (Other)

Overall Status

Recruiting

CT.gov ID

NCT05145244

Collaborator

(none)

2,400

Enrollment

Location

Anticipated Duration (Months)

82.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objectives of this prospective non-interventional study (NIS) are to assess and describe outcomes in relation to biomarkers, including whole-genome sequencing (WGS) in patients with non- small cell lung cancer (NSCLC) or breast cancer receiving treatment offered in the clinic (standard of care or included in clinical trials).

Condition or Disease	Intervention/Treatment	Phase
Non-small Cell Lung Cancer Breast Cancer	Other: NO intervention

Detailed Description

To date, there have been few studies evaluating the day- to-day effects of non-small cell lung cancer (NSCLC), and advanced (ABC) or metastatic breast cancer (mBC) and its treatment on patients in a real-world setting. There is a gap between the data from the narrowly focused low-quantity, high-quality interventional studies and less granular data collection, high-quantity real world data (RWD). Therefore, prospective, observational trials including all patients independent of biomarkers and collecting comprehensive data on each are needed.

Research question and objectives:

To describe treatment outcomes based on RWD by a complete set of clinical, socio-psychological, medico-economics data and biospecimens, including whole genome sequencing (WGS) of all patients with breast cancer and NSCLC.
To record the treatment-related adverse events and late effects experienced by patients based on PRO tools.
To perform refined biomarker analyses, including (but not limited to) whole genome sequencing, on tumor biopsies at baseline and at progression, in order to identify potential treatment targets.

Study design: Prospective, non-interventional, multicenter study of patients initiating treatment for NSCLC or breast cancer in Copenhagen (Denmark).

Population: Eligible patients will have breast cancer or NSCLC and acceptable performance status and organ function.

Data sources: Study data will be collected via a baseline site questionnaire; Patient Reported Outcomes (PRO) questions via mobile application at cycle-based intervals; and patient medical information from medical records into an eCRF at baseline and at every visit until the end of the follow-up period. Baseline WGS will be performed on diagnostic/surgical specimens after informed consent according to the Danish law of the National Genome Center. There are no specific protocol-mandated tests, procedures, or clinic visits for this study, but repeat sequential biopsies for WGS are optional at progression. All data collection for this study will occur over a 30-months period (including all treatment lines for new patients included in the period).

Study size: Up to 2400 patients diagnosed with NSCLC or breast cancer will be enrolled. Breast cancer patients will be enrolled at Rigshospitalet, and NSCLC at Rigshospitalet and Herlev Hospital. Any patient who meets the eligibility criteria will be invited to participate in the study. Eligibility will be assessed prior to enrollment during a scheduled visit.

Data analysis: Analyses will generally be descriptive and explorative in nature and will be conducted using SPSS statistical software, and no sample size calculations can be performed. All variables will be summarized descriptively through tabular displays of mean, median, ranges, and standard deviations of continuous variables and frequency distributions of categorical variables. Exploratory analyses may be conducted to examine correlations and/or other research questions (e.g., time-to-first-neutropenia using Kaplan- Meier methods or mutational status and response). No formal hypothesis testing or comparisons between treatment groups are performed.

Study Design

Study Type:

Observational

Anticipated Enrollment :

2400 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Copenhagen Master Observational Trial (C-MOT): A Prospective Investigator-initiated Observational Study to Study Biomarkers in Relation to Clinical Outcome in Patients With Non-Small Cell Lung Cancer or Breast Cancer

Actual Study Start Date :

Aug 1, 2021

Anticipated Primary Completion Date :

Dec 31, 2023

Anticipated Study Completion Date :

Dec 31, 2023

Arms and Interventions

Arm	Intervention/Treatment
Patients with newly diagnosed non-small cell lung cancer Approximately 1800 patients who are initiating Standard of care, including targeted therapy based on PD-L1 status, EGFR, ALK or ROS1 (routine biomarkers) Active clinical trials in the clinics after informed consent	Other: NO intervention No intervention
Patients with metastatic breast cancer Approximately 600 patients who are initiating Standard of care, including targeted therapy based on HER2 status and ER status (routine biomarkers) Active clinical trials in the clinics after informed consent	Other: NO intervention No intervention

Arm

Intervention/Treatment

Patients with newly diagnosed non-small cell lung cancer

Approximately 1800 patients who are initiating Standard of care, including targeted therapy based on PD-L1 status, EGFR, ALK or ROS1 (routine biomarkers) Active clinical trials in the clinics after informed consent

Other: NO intervention

No intervention

Patients with metastatic breast cancer

Approximately 600 patients who are initiating Standard of care, including targeted therapy based on HER2 status and ER status (routine biomarkers) Active clinical trials in the clinics after informed consent

Other: NO intervention

No intervention

Outcome Measures

Primary Outcome Measures

Progression free survival [3 years]
Time from baseline to progression (measured using RECIST v1.1)
Patient reported outcomes [3 years]
Health related quality of life. Two istruments will be used: EQ-5D-5L and EORTC QLQ-C30. The EQ-5D-5L will be administered at baseline and after each chemo cycle. The EORTC QLQ-C30 will be administered at baseline and 3 months after baseline.

Secondary Outcome Measures

Overall survival [3 years]
Time from baseline to death or censoring
Treatment response [3 years]
Treatment response will be measured using RECIST v1.1
Adverse events [3 years]
Adverse events will be measured using a selection of instruments from the NCI PRO-CTCAE Measurement System (Danish version 1.0). For patients with lung cancer, the selection includes question #8, 9, 15, 16, 19, 20, 24, 46, 48, 52, 53, 54, 56 as well as free text entry. For patients with breast cancer, the selection includes question #8, 15, 39, 46, 48, 52, 53, 54, 56 as well as free text entry.
Late effects [3 years]
Late effects will be measured using a selection of instruments from the NCI PRO-CTCAE Measurement System (Danish version 1.0). For patients with lung cancer, the selection includes question #8, 9, 15, 16, 19, 20, 24, 46, 48, 52, 53, 54, 56 as well as free text entry. For patients with breast cancer, the selection includes question #8, 15, 39, 46, 48, 52, 53, 54, 56 as well as free text entry.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients (≥ 18 years of age) with diagnosis of NSCLC or breast cancer amenable to medical or radiation therapy with curative or palliative intent
Evidence of a personally signed and dated informed consent form document indicating that the patient has been informed of all pertinent aspects of the study
Able to read and understand Danish
Willing and able to complete collection of data including WGS

Exclusion Criteria:

Patient with breast cancer initiating adjuvant systemic therapy
In the judgment of the investigator, the patient's life expectancy is fewer than 3 months at the time of diagnosis of NSCLC or breast cancer